Article contents
Optimising neuroleptic treatment for psychotic illness
Published online by Cambridge University Press: 02 January 2018
Abstract
The release of the antipsychotic agents risperidone, sertindole and olanzepine forces difficult choices upon clinicians. The new compounds are better tolerated than neuroleptics, expensive and their long-term side-effects unknown. These choices can be made easier by the dose and side-effect minimisation procedure set out below, which aims to produce the greatest benefit and least harm from conventional neuroleptics.
- Type
- Original Papers
- Information
- Creative Commons
- This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Copyright
- Copyright © 1998 The Royal College of Psychiatrists
References
- 2
- Cited by
eLetters
No eLetters have been published for this article.